Lubiprostone
These highlights do not include all the information needed to use LUBIPROSTONE CAPSULES safely and effectively. See full prescribing information for LUBIPROSTONE CAPSULES. LUBIPROSTONE capsules, for oral use Initial U.S. Approval: 2006
e17b521e-2c25-4bef-82f9-7916fa79bca4
HUMAN PRESCRIPTION DRUG LABEL
May 27, 2022
Teva Pharmaceuticals, Inc.
DUNS: 022629579
Products 2
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
Lubiprostone
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (11)
Lubiprostone
Product Details
FDA regulatory identification and product classification information